General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine
(2000; 80 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoAcknowledgements
Ver el documentoForeword
Abrir esta carpeta y ver su contenidoIntroduction
Abrir esta carpeta y ver su contenido1. Methodologies for Research and Evaluation of Herbal Medicines
Abrir esta carpeta y ver su contenido2. Methodologies for Research and Evaluation of Traditional Procedure-Based Therapies
Abrir esta carpeta y ver su contenido3. Clinical Research
Abrir esta carpeta y ver su contenido4. Other Issues and Considerations
Ver el documentoReferences
Abrir esta carpeta y ver su contenidoAnnexes
Cerrar esta carpetaAnnex I. Guidelines for the Assessment of Herbal Medicinesa
Ver el documentoIntroduction
Ver el documentoAssessment of Quality
Ver el documentoAssessment of Safety
Ver el documentoAssessment of Efficacy
Ver el documentoIntended Use
Ver el documentoUtilization of these Guidelines
Abrir esta carpeta y ver su contenidoAnnex II. Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicinesa
Abrir esta carpeta y ver su contenidoAnnex III. Report of a WHO Consultation on Traditional Medicine and AIDS: Clinical Evaluation of Traditional Medicines and Natural Productsa
Abrir esta carpeta y ver su contenidoAnnex IV. Definition of Levels of Evidence and Grading of Recommendationa
Abrir esta carpeta y ver su contenidoAnnex V. Guidelines for Levels and Kinds of Evidence to Support Claims for Therapeutic Goodsa
Abrir esta carpeta y ver su contenidoAnnex VI. Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Productsa
Abrir esta carpeta y ver su contenidoAnnex VII. Guidance for Industry: Significant Scientific Agreement in the Review of Health Claims for Conventional Foods and Dietary Supplementsa
Abrir esta carpeta y ver su contenidoAnnex VIII. Guideline for Good Clinical Practicea
Abrir esta carpeta y ver su contenidoAnnex IX. WHO QOL (Quality of Life) User Manual: Facet Definitions and Response Scalesa
Ver el documentoAnnex X. Participants in the WHO Consultation on Methodologies for Research and Evaluation of Traditional Medicine
 

Assessment of Quality

Pharmaceutical assessment

This should cover all important aspects of the quality assessment of herbal medicines. It should be sufficient to make reference to a pharmacopoeia monograph if one exists. If no such monograph is available, a monograph must be supplied and should be set out as in an official pharmacopoeia.

All procedures should be in accordance with good manufacturing practices.

Crude plant material

The botanical definition, including genus, species and authority, should be given to ensure correct identification of a plant. A definition and description of the part of the plant from which the medicine is made (e.g. leaf, flower, root) should be provided, together with an indication of whether fresh, dried or traditionally processed material is used. The active and characteristic constituents should be specified and, if possible, content limits should be defined. Foreign matter, impurities and microbial content should be defined or limited. Voucher specimens, representing each lot of plant material processed, should be authenticated by a qualified botanist and should be stored for at least a 10-year period. A lot number should be assigned and this should appear on the product label.

Plant preparations

Plant preparations include comminuted or powdered plant materials, extracts, tinctures, fatty or essential oils, expressed juices and preparations whose production involves fractionation, purification or concentration. The manufacturing procedure should be described in detail. If other substances are added during manufacture in order to adjust the plant preparation to a certain level of active or characteristic constituents or for any other purpose, the added substances should be mentioned in the manufacturing procedures. A method for identification and, where possible, assay of the plant preparation should be added. If identification of an active principle is not possible, it should be sufficient to identify a characteristic substance or mixture of substances (e.g. “chromatographic fingerprint”) to ensure consistent quality of the preparation.

Finished product

The manufacturing procedure and formula, including the amount of excipients, should be described in detail. A finished product specification should be defined. A method of identification and, where possible, quantification of the plant material in the finished product should be defined. If the identification of an active principle is not possible, it should be sufficient to identify a characteristic substance or mixture of substances (e.g. “chromatographic fingerprint”) to ensure consistent quality of the product. The finished product should comply with general requirements for particular dosage forms.

For imported finished products, confirmation of the regulatory status in the country of origin should be required. The WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce should be applied.

Stability

The physical and chemical stability of the product in the container in which it is to be marketed should be tested under defined storage conditions and the shelf-life should be established.

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019